A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
EudraCT / EU CT No
2025-522267-15-00
Protocol No
MK1045-005
Trial information
Medical condition
ALL
Trial phase
Phase 2/3
Sponsor
Merch Sharp & Dohme
Start date
31/07/2026
Main objective
To compare the efficacy and safety of MK-1045 versus blinatumomab in participants with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL), with primary endpoints likely including complete remission rate and/or overall survival.
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Ioannina
University General Hospital of Ioannina
Department of Hematology, Clinical Studies Office
Eleftheria Hatzimichael
Olga Siarabi
2651099650
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.
